McCormack Paul L, Robinson Dean M
Wolters Kluwer Health Adis, Auckland, New Zealand.
CNS Drugs. 2009;23(1):71-9. doi: 10.2165/0023210-200923010-00005.
Eslicarbazepine acetate, a prodrug of eslicarbazepine (S-licarbazepine), is a novel, voltage-gated sodium channel antagonist under development for the adjunctive treatment of adult patients experiencing treatment-refractory partial-onset seizures. * In phase III trials, eslicarbazepine acetate 800 and 1200 mg once daily significantly reduced seizure frequency compared with placebo over 12 weeks of maintenance treatment in adults experiencing partial-onset seizures who were taking 1-3 concomitant antiepileptic drugs. * During long-term, open-label treatment for up to 1 year, eslicarbazepine acetate at a median dosage of 800 mg once daily produced sustained reductions from baseline in seizure frequency. * Long-term treatment with eslicarbazepine acetate significantly improved from baseline health-related quality of life as assessed by the Quality-of-Life in Epilepsy Inventory-31 instrument. Similarly, eslicarbazepine acetate significantly reduced depressive symptoms assessed by the Montgomery-Asberg Depression Rating Scale. * Eslicarbazepine acetate was generally well tolerated in clinical trials. The majority of treatment-emergent adverse events were of mild to moderate severity and most occurred early in treatment.
醋酸艾司利卡西平是艾司利卡西平（S-利卡西平）的前体药物，是一种正在开发用于辅助治疗难治性成人部分性发作的新型电压门控钠通道拮抗剂。* 在III期试验中，对于正在服用1 - 3种抗癫痫药物的部分性发作成人患者，在维持治疗的12周内，每日一次服用800毫克和1200毫克醋酸艾司利卡西平与安慰剂相比，癫痫发作频率显著降低。* 在长达1年的长期开放标签治疗期间，每日一次中位剂量800毫克的醋酸艾司利卡西平使癫痫发作频率较基线持续降低。* 通过癫痫生活质量量表-31评估，醋酸艾司利卡西平长期治疗使与健康相关的生活质量较基线显著改善。同样，通过蒙哥马利-艾斯伯格抑郁量表评估，醋酸艾司利卡西平显著减轻了抑郁症状。* 醋酸艾司利卡西平在临床试验中总体耐受性良好。大多数治疗中出现的不良事件为轻度至中度严重程度，且大多在治疗早期出现。
